We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+1.17%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$394M
AUM Growth
+$59.8M
(+18%)
Cap. Flow
+$62M
Cap. Flow
% of AUM
15.71%
Top 10 Holdings %
Top 10 Hldgs %
57.09%
Holding
61
New
12
Increased
17
Reduced
12
Closed
17
Top Buys
| 1 |
McKesson
MCK
|
+$19.9M |
| 2 |
AbCellera Biologics
ABCL
|
+$18.6M |
| 3 |
DexCom
DXCM
|
+$9.09M |
| 4 |
Janux Therapeutics
JANX
|
+$8.92M |
| 5 |
BridgeBio Pharma
BBIO
|
+$7.53M |
Top Sells
| 1 |
Kelly Services Class A
KELYA
|
+$10.5M |
| 2 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$8.74M |
| 3 |
Alkermes
ALKS
|
+$6.63M |
| 4 |
OrthoPediatrics
KIDS
|
+$5.76M |
| 5 |
Option Care Health
OPCH
|
+$5.68M |
Sector Composition
| 1 | Healthcare | 97.26% |
| 2 | Industrials | 2.74% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADC Therapeutics
ADCT
$163M
| $30.4M | 7.7% |
9,636,237
+66,237
| +0.7% | +$209K |
|
|
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $29.6M | 7.51% |
1,028,843
-321,137
| -24% | -$8.74M |
|
|
3
BridgeBio Pharma
BBIO
$16.2B
| $27.7M | 7.02% |
1,086,810
+286,810
| +36% | +$7.53M |
|
|
4
AbCellera Biologics
ABCL
$2.06B
| $23.6M | 5.99% |
9,079,539
+6,726,906
| +286% | +$18.6M |
|
5
MeiraGTx Holdings
MGTX
$1.16B
| $20.4M | 5.18% |
4,900,570
+547,870
| +13% | +$2.37M |
|
6
Roivant Sciences
ROIV
$25.1B
| $19.9M | 5.04% |
1,721,512
-278,488
| -14% | -$3.17M |
|
7
Shattuck Labs
STTK
$647M
| $19.8M | 5.03% |
5,678,726
+1,008,726
| +22% | +$3.76M |
|
8
Mirum Pharmaceuticals
MIRM
$7.38B
| $18.2M | 4.61% |
465,825
+151,025
| +48% | +$6.02M |
|
9
Zimmer Biomet
ZBH
$17.4B
| $17.9M | 4.53% |
165,602
-4,398
| -3% | -$480K |
|
|
10
McKesson
MCK
$93.2B
| $17.7M | 4.49% |
+35,822
| New | +$19.9M |
|
11
Kura Oncology
KURA
$1.01B
| $13.8M | 3.49% |
705,109
+75,209
| +12% | +$1.52M |
|
12
Schrodinger
SDGR
$1.22B
| $13M | 3.29% |
700,000
+330,739
| +90% | +$6.79M |
|
13
Zymeworks
ZYME
$1.81B
| $11.5M | 2.92% |
917,599
-262,401
| -22% | -$2.86M |
|
|
ACCD
14
DELISTED
Accolade Inc
ACCD
| $10.8M | 2.74% |
2,801,598
+1,312,073
| +88% | +$5.14M |
|
|
15
DexCom
DXCM
$28.1B
| $10.7M | 2.72% |
160,000
+110,683
| +224% | +$9.09M |
|
16
Syndax Pharmaceuticals
SNDX
$2.08B
| $10.7M | 2.7% |
554,103
+2,559
| +0.5% | +$52.9K |
|
17
Immunovant
IMVT
$8.19B
| $10.5M | 2.68% |
370,000
+45,000
| +14% | +$1.33M |
|
18
Cytokinetics
CYTK
$11.2B
| $10.2M | 2.58% |
192,700
-37,300
| -16% | -$2.08M |
|
|
19
Janux Therapeutics
JANX
$978M
| $9.31M | 2.36% |
+205,000
| New | +$8.92M |
|
20
Prothena Corp
PRTA
$441M
| $8.09M | 2.05% |
483,467
+196,541
| +68% | +$4.23M |
|
21
Neurocrine Biosciences
NBIX
$17.3B
| $7.14M | 1.81% |
62,000
+35,000
| +130% | +$4.8M |
|
22
PUT
iShares S&P 100 ETF
OEF
$20.5B
| $6.41M | 1.62% |
+29,000
| New | +$7.75M |
|
23
Erasca
ERAS
$6.61B
| $5.42M | 1.37% |
1,984,010
-765,990
| -28% | -$2.16M |
|
24
Haemonetics
HAE
$3.48B
| $5.22M | 1.32% |
+65,000
| New | +$5.25M |
|
25
LivaNova
LIVN
$4.36B
| $4.73M | 1.2% |
+90,000
| New | +$4.46M |
|
Similar funds
PL
BFC
ACM
FFWA
SAM
CBB
AIG
IA